EIGR Eiger BioPharmaceuticals Inc.

12.68
0  0%
Previous Close 12.68
Open
Price To Book 4.33
Market Cap 310,597,196
Shares 24,495,047
Volume 1
Short Ratio
Av. Daily Volume 225,720
Stock charts supplied by TradingView

NewsSee all news

  1. Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

    PALO ALTO, Calif., Jan. 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for

  2. Eiger Updates on 2019 Progress and 2020 Milestones Expected

    PALO ALTO, Calif., Jan. 6, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare

  3. Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

    PALO ALTO, Calif., Dec. 16, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for

  4. Eiger to Present at Jefferies 2019 London Healthcare Conference

    PALO ALTO, Calif., Nov. 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  5. Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019

    PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ultra-rare

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released October 16, 2018 - endpoints met. Data presented at ENDO March 25, 2019.
Avexitide (Exendin 9-39)
Post-Bariatric Hypoglycemia (PBH)
Phase 2 LIMT data noted 36% curable virologic response at 24 weeks post-treatment - April 11. 2019.
Pegylated Interferon Lambda (LIMT HDV)
Hepatitis delta virus (HDV)
Phase 3 enrolment to be completed in 2020. Top-line data planned in 2021.
Lonafarnib - D-LIVR
Chronic hepatitis delta virus (HDV)
Phase 2 trial did not meet endpoints - January 16, 2018.
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2 data released October 16, 2018 did not meet endpoints.
Ubenimex - ULTRA
Secondary lymphedema
Phase 2b negative data released April 2015. Formerly CLDN pre-merger
MYDICAR - CUPID 2 Trial
Ischemic or dilated cardiomyopathy
Phase 2 additional data expected at EASL and AASLD 2020
Pegylated interferon lambda + ritonavir (RTV)-boosted lonafarnib (LNF) - LIFT
Hepatitis delta virus (HDV)
NDA rolling submission commenced December 16, 2019. To be completed 1Q 2020.
Lonafarnib
Hutchinson-Gilford Progeria Syndrome (HGPS)

Latest News

  1. Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer

    PALO ALTO, Calif., Jan. 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late-stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for

  2. Eiger Updates on 2019 Progress and 2020 Milestones Expected

    PALO ALTO, Calif., Jan. 6, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare

  3. Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies

    PALO ALTO, Calif., Dec. 16, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a late stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for

  4. Eiger to Present at Jefferies 2019 London Healthcare Conference

    PALO ALTO, Calif., Nov. 15, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  5. Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019

    PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ultra-rare

  6. Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    PALO ALTO, Calif., Nov. 7, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  7. Eiger to Present at Cantor 2019 Global Healthcare Conference

    PALO ALTO, Calif., Sept. 27, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today

  8. Eiger BioPharmaceuticals to Participate in September Conferences

    PALO ALTO, Calif., Aug. 29, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today